4889Renascience4889 info
$2.45info-1.13%24h
Global rank27798
Market cap$31.19M
Change 7d-1.13%
YTD Performance-18.22%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Renascience (4889) Stock Overview

    Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.

    4889 Stock Information

    Symbol
    4889
    Address
    401 Kyodo BuildingTokyo, 103-0023Japan
    Founded
    -
    Trading hours
    -
    Website
    https://www.renascience.co.jp
    Country
    🇯🇵 Japan
    Phone Number
    81 3 6262 0873

    Renascience (4889) Price Chart

    -
    Value:-

    Renascience Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.45
    N/A
    Market Cap
    $31.19M
    N/A
    Shares Outstanding
    12.71M
    N/A
    Employees
    3.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org